Meril Life Sciences launches indigenously researched and developed thin-strut bioresorbable scaffold, MeRes100 - BRS, in India
Kolkata, Mar 10 (UNI) Meril Life Sciences today announced the launch of its indigenously researched and developed bioresorbable scaffold (BRS) MeRes100 in India.
Bioresorbable scaffolds are non-metallic, non-permanent mesh tubes, similar to stents, that dissolve over time after ensuring the previously blocked artery is opened via a routine angioplasty procedure. This novel therapy option, which can meaningfully treat an identified subset of the patient population, will be launched in a phased, sequential manner to ensure adherence to best clinical practices and continued development of clinical research and long-term evidence.
Date Time
Samples from public spaces could show how coronavirus spreads through air
A new study will explore whether tiny airborne droplets and particles can spread coronavirus in settings like supermarkets, schools and busy streets.
Led by Imperial College London and the University of Surrey, the research will collect samples from a wide range of public spaces to see if microscopic droplets suspended in the air, from coughing or talking, can carry and disperse ‘live’ COVID-19 virus (called SARS-CoV-2) capable of causing infection.
The work will also look at whether the virus can be dispersed further afield by piggybacking on particulate matter in the atmosphere, such as small particles from vehicle pollution or dust.
I am a full professor and member of the Center for Health Law Studies at Saint Louis University School of Law. She is also co-founder and Executive Director of Saint Louis University’s Institute for Healing Justice and Equity. I am Co-Principal Investigator of the Robert Wood Johnson Foundation grant entitled, “Are Cities and Counties Ready to Use Racial Equity Tools to Influence Policy?” Recently, I authored a report entitled, Protecting Workers that Provide Essential Services, in the COVID-19 PolicyPlaybook and co-authored, Racism is a Public Health Crisis. Here’s How to Respond. Using empirical data, her research explores the ways in which discrimination prevents vulnerable communities from attaining equal access to quality health care, resulting in health inequities. My work has been cited in THE OXFORD HANDBOOK OF PUBLIC HEALTH ETHICS (2019), DOLGIN & SHEPHARD, BIOETHICS AND THE LAW (4th ed 2019), and MARK HALL, ET AL, HEALTH CARE LAW AND ETHICS (9th ed 2018). She earned
Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease Transformative Technology Now Available for Calcified Coronary Plaque
February 16, 2021 07:00 ET | Source: Shockwave Medical, Inc. Shockwave Medical, Inc. Santa Clara, California, UNITED STATES
SANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval for severely calcified coronary artery disease from the U.S. Food and Drug Administration (FDA). The innovative technology, which was granted Breakthrough Device designation by the FDA, is a novel application of lithotripsy, an approach that has been used for decades to safely break up kidney stones. With this approval, IVL is now commercially av